
Investor Relations
Corporate Profile
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
- Change
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Mar 30
2023
2023
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Learn More >
Mar 14
2023
2023
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Learn More >
Mar 02
2023
2023
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Learn More >
Mar 01
2023
2023
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
Learn More >
Feb 28
2023
2023
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Learn More >
Feb 21
2023
2023
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Learn More >
Feb 01
2023
2023
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
Learn More >
Jan 25
2023
2023
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Learn More >
Jan 24
2023
2023
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
Learn More >
Jan 17
2023
2023
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Learn More >
Events
Feb 28, 2023 at 5:00 PM EST
Mar 6, 2023 at 11:10 AM EST
Mar 14, 2023 at 12:00 PM EDT